Navigation Links
IMPAKT -- Translational research breast cancer conference
Date:4/11/2013

n as possible:
  • Biomarker data including
    • Predicting risk for late metastasis: the PMA50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer: a study on 1,478 patients from the ABCSG-8 trial (53 O)
    • Prognostic and predictive value of IHC4 and ERB1 in the integroup exemestane study (IES) on behalf of the pathies investigators (55 O)
    • Comparison of five different scores for the prediction of late recurrence for oestrogen receptor positive breast cancer (54 O)
    • Predictive value of AKT/mTOR pathway immunohistochemical (IHC) biomarkers for response to pre-operative trastuzumab vs. trastuzumab + everolimus in patients with early breast cancer: UNICANCER RADHER trial results (56 O)
  • Heterogeneity of breast cancer including
    • Contribution of analytical, pre-analytical and intra-tumoral heterogeneity to variance in gene expression measurements from human breast cancers (40 O)
    • Heterogeneity of genomic signatures in breast cancer core biopsy (41 O)
    • Assessment of Genetic Alterations in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer From the BOLERO-2 Trial by Next-Generation Sequencing (42 O)

Press conference

Thursday, 2 May 2013, 10:45-11:45 (CEST)

Hosts: Martine Piccart, Jules Bordet Institute, Head of Chemotherapy Unit, Brussels, Belgium, IMPAKT Co-Founder Peter Dubsky, Vienna General Hospital (AKH) - Medizinische Universitt Wien, Vienna, Austria, IMPAKT2013 Scientific Chair Andrew Tutt, King's College London Guy's Hospital, London, United Kingdom, IMPAKT2013 Executive Chair

BIG and ESMO welcome media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the Media Policy < '/>"/>

Contact: ESMO PRess Office
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Fourth IMPAKT Breast Cancer Conference
2. Hot topics in translational bone research at IOF-ESCEO 3rd Pre-Clinical Symposium
3. Autism Speaks and SAGE® Labs develop rat models for translational autism research
4. Elsevier launches new open access journal: Applied and Translational Genomics
5. BUSM researchers identify novel approach to study COPD and treatment efficacy
6. LSUHSC research discovers new drug target for metastatic breast cancer
7. Researchers call for marine observation network
8. Biofilms help Salmonella survive hostile conditions, Virginia Tech researchers say
9. Feinstein Institute collaborates with GSK, UPenn, MIT to research bodys electrical impulses
10. U-M researchers find new way to clear cholesterol from the blood
11. New cutting-edge cell research will lead to safer medical experiments on humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2House fly genome reveals expanded immune system 2
... understand extreme sea creaturesExtraordinary creatures who inhabit extreme underwater ... three-year project. These deep-sea communities could reveal an evolutionary ... give us clues to how life could exist onother ... - incredibly hot environments in the deep sea - ...
... how Listeria monocytogenes, which causes a major ... and hide from the body's immune system. They believe ... , The Listeria bacterium, found in ... undercooked and unpasteurized food, causing flu-like symptoms or gastrointestinal ...
... blood pressure-lowering gene into cells and enables that gene to ... to take gene therapy for the disorder a step closer ... a report released online in the Proceedings of the National ... the leading causes of death and disability in adults worldwide," ...
Cached Biology News:Gene discovery sheds light on causes of rare disease, cancer 2Gene therapy to lower blood pressure just enough 2
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... (Nasdaq and SWX: BMRN) announced today that AnGes ... Japan, has,received approval for its Marketing Application for ... and Welfare,(MHLW) for the treatment of patients with ... to work with AnGes in bringing the first ...
... Company Cites Important Progress With Needle-free Vaccine Technology and ... Bird Flu ... March 31, 2008, IRVING, Texas, March 31 Carrington,Laboratories, Inc. ... net loss of $9.8 million, or ($0.90) per basic and,diluted share, ...
... Inc. (NYSE: CRY ),(the "Company"), a biomaterials, ... entered into a credit facility with GE Healthcare,Financial ... in revolving,credit for working capital, acquisitions and other ... at which time the outstanding,principal balance will be ...
Cached Biology Technology:Naglazyme Approved by Japanese Ministry of Health 2Naglazyme Approved by Japanese Ministry of Health 3Naglazyme Approved by Japanese Ministry of Health 4Carrington Reports 2007 Financial Results 2Carrington Reports 2007 Financial Results 3Carrington Reports 2007 Financial Results 4Carrington Reports 2007 Financial Results 5Carrington Reports 2007 Financial Results 6Carrington Reports 2007 Financial Results 7CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services 2CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services 3
... High signal and low background ,This ... several ten times higher than obtained with ... optimized for primary and secondary antibodies, which ... S/N ratio. , Wide versatility ,It ...
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse anti human pro-Relaxin-2...
Biology Products: